RespireRx Pharmaceuticals — Cortex Pharmaceuticals — Investor Presentation (October 2015)
34 slides from RespireRx Pharmaceuticals's investor presentation, Oct 20, 2015
Slide 1: Cortex Pharmaceuticals, Inc.
a] (OXTEX PHARMACEUTICALS, INC. Cortex Pharmaceuticals, Inc. OTC QB:CORX James S. Manuso, Ph.D., President & CEO
Slide 2: Forward-Looking Statements
orwa nt ooking The matters discussed in this presentation that are not historical facts are "forward- looking statements." Forward-looking statements include, but are not limited to, statements containing the words "believes," "anticipates," "intends," "expects," "projects" and words of similar impo
Slide 3: Breath is the universal factor of life
"Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit the same word means both breath and life." bene Abbot George Burke —_
Slide 4: Innovative Therapeutics for Respiratory Diseases
: = ey : Innovative upritaness for Respiratory Diseases » Two drug platforms from two companies v Four Phase 2 or Phase 2-ready programs Blockbuster markets v v IP protection with the ability to add additional IP v Multiple opportunities for strategic collaborations v Availability of non-dilutive fi
Slide 5: Company Focus
Company Focus » Sleep Apneas e Dronabinol for Obstructive Sleep Apnea (OSA) ° Ampakines for Central Sleep Apnea (CSA) » Drug-induced Respiratory Depression (RD) - Ampakines ° Semi-acute use — post-surgical pain management with opiates ° Acute use — surgical anesthesia ° Chronic use — Outpatient pain
Slide 6: Respiratory Diseases Product Pipeline
Respiratory Diseases Product Pipeline Stage of Development Compound Indication Pre-clinical Phase1 Phase 2 5 Obstructive Sleep Bronatinel | ie ——<$—<$<<<— Central Sleep Apnea CX1739 Opiate-induced RD Spinal Damage/Pompe Combination CX717 Formulation with Opiates for Reduced RD 0x1942 Drug-induced Re
Slide 7: Sleep Apnea
Sleep Apnea » Sleep Apnea ° Repetitive episodes of airflow cessation fapnea) or reduction (hypopnea) for more than 10 seconds during sleep ° Three types: Obstructive, Central & Mixed » The Sleep Apnea Market is Large ° 18 million U.S. adults suffer from moderate or severe sleep apneas e Market poten
Slide 8: Obstructive Sleep Apnea (OSA)
Obstructive Sleep Apnea (OSA) » Obstructive Sleep Apnea (OSA): a decrease or complete halt in airflow during sleep e Induced by relaxation of muscles during sleep ° Soft tissue in back of throat collapses and obstructs upper airway » Significant morbidity due to stroke, hypertension, heart failure,
Slide 9: CPAP Efficacy is Greatly Limited by Patient Compliance
CPAP Efficacy is Greatly Limited by Patient Compliance Works as an air splint to keep upper airway open during sleep 30% of diagnosed patients never initiate CPAP treatment when prescribed a machine Over 50% of patients stop using CPAP in the first year Many CPAP users wear the : device for less tha
Slide 10: Dronabinol: a Breakthrough Treatment for OSA
Dronabinol: a Breakthrough Treatment for OSA » Mechanism of Action Dronabinol is (D-9)THC, a cannabinoid agonist » Stage of Development Schedule Ill drug available by prescription, with a low risk of addiction Approved for the treatment of anorexia in AIDS patients and nausea and vomiting in cancer
Slide 11: Completed Phase 2A Trial of Dronabinol in OSA
Completed Phase 2A Trial of Dronabinol in OSA » Randomized, double-blind, placebo-controlled dose escalation study in 22 patients with OSA » Placebo (N=5) or dronabinol (N=17) for 21 days e 2.5, 5 and 10 mg/night studied with weekly dose escalation » Overnight polysomnogram (PSG) at baseline, and af
Slide 12: Dronabinol Proven to Reduce Apnea in OSA Subjects
Dronabinol Proven to Reduce Apnea in OSA Subjects AHI Mean % Change from Baseline to End of Treatment P=0.17 Dronabinol Placebo P<0.01 Reduction in Sleep Apnea 6 8
Slide 13: AAHI versus Baseline
AAHI versus Baseline Li of Dose and Time n=17 n=13 n=8 The plasma half-life of dronabinol is 2 — 4 hours. = 1st Half = 2nd Half 8
Slide 14: Ongoing Dronabinol Phase 2B
Ongoing Dronabinol Phase 2B » 4 major centers, fully funded by NIH » Potentially pivotal for an accelerated NDA » 120 subjects (40/group, 6 wks dosing) » Doses: Placebo, 2.5 mg, 10 mg qd » Completion by Q3/2016 » Meet with FDA in Q4/2016 to determine registration path forward —_
Slide 15: Protecting Dronabinol in the Market
Protecting Dronabinol in the Market » Issued Method-of-Use patent for dronabinol in OSA ° Expires in 2025 » Schedule Ill drug: off-label use monitored by US government, discouraging generic manufacturers from selling off-label » Off-label use of generics and medical marijuana are not covered by insu
Slide 16: First therapeutic available for OSA
First therapeutic available for OSA Ease of Use/Better Patient Compliance Low cost Safe and effective Potential for better cardiovascular outcomes Changes the nature of OSA treatment Broadly expands prescriber base from sleep specialists to include primary care physicians and cardiologists Recurring
Slide 17: Central Sleep Apnea
Central Sleep Apnea » Caused by a lack of drive from the brain to breathe during sleep » Manifestations of CSA ° 70% of chronic narcotic users ° Up to 40% of heart failure patients ° 5% of sleep apnea patients have idiopathic » No therapeutic or device is approved for the indication —_
Slide 18: Reduce Mortality in Heart Failure Patients
Reduce Mortality in Heart Failure Patients 68 AHI less than 5 per hour *, eee Al equal or greater than Sper hour ‘Survival % 8s 8 8 ses 8 ° 0 DDD © 0H MH % Mm Ww MO BO HO 10 Months: ‘Survival of heart failure (HF) pationts with or without central sleep apnea. (CSA) after accounting forall other conf
Slide 19: Ampakines — A Novel Class of Drugs
AMPAKINES — A NOVEL CLASS OF DRUGS AMPA Receptors Mediate Synaptic Transmission in the Brain Glutamate is the major excitatory neurotransmitter in the CNS Fast excitatory transmission is mediated by AMPA-type glutamate receptors Ampakines are positive, allosteric modulators of the AMPA-type glutamat
Slide 20: PreBötzinger Complex
PreBétzinger PreBétzinger Complex Complex Neurons in this brainstem region control inspiratory breathing rhythm + PreBotC neurons use AMPA receptors for signaling Initial research conducted by Dr. J. Greer, U. Alberta ° Opiates and other depressants mediate their Ren et al, Anesthesiology. 110/136-1
Slide 21: CX1739: A Third Generation, Oral Ampakine
CX1739: A Third Generation, Oral Ampakine in Phase 2 » Targeted Indications e Central Sleep Apnea (CSA) e Reversal and prevention of opiate-induced Respiratory Depression (RD) e Combination formulation with an opiate for treatment of chronic pain » Stage of Development e Successfully completed Phase
Slide 22: CX1739: Completed Phase 2A in CSA
CX1739: Completed Phase 2A in CSA Design Randomized, double-blind, placebo-controlied study Population | 20 adults with all types of moderate to severe sleep apnea (16 given CX1739; 4 given Placebo) Dosing Each subject received either placebo or a single dose of 900mg CX1739 one hour before lights o
Slide 23: Responders by Measure Group
Measure Group No. Responders* ‘Apnea-Hypopnea Index x1 739 ; Sh45 (AHI) Placebo 0/4 Apnea-Hypopnea Time CX1739 5/15) (AHT) Placebo 0/4 * Aresponder has at least a 40% decrease in the respective parameter
Slide 24: Apnea Index
Apnea Index (Events/nr) BRBB Obstructive Apneas [ tT (Events/nr) Apnea Index Mixed Apneas 6 5. so SEs. a 35° Pings Pack : a °. -. < &
Slide 25: Drug-induced Respiratory Depression
Drug-induced Respiratory Depression RD is the most frequent lethal side effect of opiate use Acute and Semi-Acute Use of opiates ° ~25M patients/year at risk for RD (hospitalized, peri- and post- surgical opiate patients) Chronic Opiate Use e Proprietary combination formulation for use in patients w
Slide 26: Respiratory Depression in Humans
Respiratory Depression in in ‘Humans » Two clinical studies were run in normal, healthy volunteers with CX717, a second-generation Ampakine » Moderate Respiratory Depression was induced experimentally by infusion of the opioid, Alfentanil » Respiratory and analgesia end-points were measured
Slide 27: Breathing Rate
Breathing Rate 16 *k _s_. C—Placebo Gaggcx717 12: ™*P<0.01 NS - Not Significant Breaths/min eo Baseline +Alfentanil +Naloxone Data are expressed as the basal respiratory rate. N= 15 and 16 per group. CX717 dose is 1500mg. ar
Slide 28: Rescue Therapy Analgesia
ng Rescue Therapy Analgesia 2.0: C-Placebo @agcx717 = a NS Pain Sensitivity = S Ss a Delivery of a electrical stimulation to finger 0.0: Baseline +Alfentanil +Naloxone Data are expressed as the pain sensitivity, normalized to the Baseline measurement. N= 15 and 16 per group. CX717 dose is 1500mg 28
Slide 29: Respiratory Diseases Product Pipeline
Respiratory Diseases Product Pipeline Stage of Development Compound Indication Pre-clinical Phase1 Phase 2 5 Obstructive Sleep Bronatinel | ie ——<$—<$<<<— Central Sleep Apnea CX1739 Opiate-induced RD Spinal Damage/Pompe Combination CX717 Formulation with Opiates for Reduced RD 0x1942 Drug-induced Re
Slide 30: Key Objectives for the Next Months
Key Objectives for the Next 12 Months (Pending Financing) Compound Indication Status Estimated Estimated Start Date Completion Dronabinol Obstructive Sleep Apnea Phase 2B Underway 3Q2016 Opiate-induced RD Phase 2A 1Q2016 2Q2016 CX1739 Central Sleep Apnea Phase 2A 2Q2016 4Q2016 Spinal Cord Injury, SO
Slide 31: Common Stock
Common Stock Common Stock Equivalents of all Convertibles Common Stock Equivalents of all Options and Warrants 413,477 63,744 477,221 112,602 (16,668) 95,934 144,991 235,256 380,247 671,070 282,332 953,402 ey
Slide 32: Management and Directors
Management and Directors James Manuso Arnold Lippa Jeff Margolis Robert Weingarten Richard Purcell Katie MacFarlane James Sapirstein John Greer President, CEO & Vice Chairman CSO & Chairman VP, Secretary/Treasurer, Director CFO, Director Senior VP, R&D Director CCO Agile Therapeutics Director CEO Co
Slide 33: Innovative Therapeutics for Respiratory Diseases
: = ey : Innovative upritaness for Respiratory Diseases » Two drug platforms from two companies v Four Phase 2 or Phase 2-ready programs Blockbuster markets v v IP protection with the ability to add additional IP v Multiple opportunities for strategic collaborations v Availability of non-dilutive fi
Slide 34: Cortex Pharmaceuticals, Inc.
a] (OXTEX PHARMACEUTICALS, INC. Cortex Pharmaceuticals, Inc. OTC QB:CORX James S. Manuso, Ph.D., President & CEO
Cortex Pharmaceuticals — Investor Presentation (October 2015) on 6ix